Close Menu

NEW YORK – Finnish molecular diagnostics company Mobidiag said today that it has received CE-IVD marking for its Novodiag Stool Parasites test for the detection of intestinal parasites from stool samples.

The Novodiag Stool Parasites syndromic test combines real-time PCR and microarray technologies to detect more than 95 percent of intestinal parasites, the firm said. Its test detects the presence of nucleic acid markers corresponding to the identification of the most common protozoan, helminths, and microsporidia from stool samples.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.